Janux Therapeutics (JANX) Operating Expenses (2020 - 2026)

Janux Therapeutics (JANX) has reported Operating Expenses for 7 consecutive years, with $37.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 8.74% year-over-year to $37.9 million; the TTM figure through Mar 2026 stood at $170.7 million (up 38.88% YoY), while the FY2025 annual figure was $167.7 million, up 53.21% from the prior year.
• Operating Expenses declined to $37.9 million in Q1 2026 per JANX's latest filing, from $42.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $45.3 million in Q3 2025 and bottomed at $15.1 million in Q1 2022.
• Historically, Operating Expenses has averaged $27.8 million across 5 years, with a median of $22.3 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 467.98% — and 2023, when it fell 11.9%.
• Janux Therapeutics' Operating Expenses stood at $21.1 million in 2022, then fell by 11.9% to $18.6 million in 2023, then jumped by 56.05% to $29.0 million in 2024, then soared by 46.1% to $42.4 million in 2025, then declined by 10.51% to $37.9 million in 2026.
• Business Quant data shows JANX's Operating Expenses at $37.9 million in Q1 2026, $42.4 million in Q4 2025, and $45.3 million in Q3 2025.